What is the recommended starting dose and titration schedule for testosterone (AndroGel 5% gel or injectable testosterone) in a female-to-male (FtM) transgender patient?

FtM HRT Dosage Recommendations

For female-to-male transgender patients, start with testosterone gel (AndroGel 5%) at 5 g daily applied to shoulders/upper arms, OR injectable testosterone enanthate/cypionate at 50-100 mg every 1-2 weeks, titrating to achieve mid-normal male testosterone levels (400-700 ng/dL). 1, 2

Starting Doses by Formulation

Transdermal Gel (AndroGel 5%)

• Initial dose: 5 g daily (50 mg testosterone) applied to clean, dry skin of shoulders, upper arms, or abdomen 2
• Allow gel to dry before dressing; avoid fire/flames until dry
• Wash hands thoroughly after application
• Check testosterone level after 1 week on treatment, then adjust 3, 1
• Can increase to 7.5 g or 10 g daily if levels remain subtherapeutic
• Lower starting doses (2.5-5 g daily) are appropriate for patients seeking slower masculinization 4

Injectable Testosterone (Enanthate or Cypionate)

• Initial dose: 50-100 mg every 2 weeks intramuscularly 1, 5
• Alternative dosing: 25-50 mg weekly for more stable levels 5, 6
• Subcutaneous administration is equally effective at average dose of 46.4 mg weekly 6
• Measure testosterone midway between injections for dose adjustment 3, 1

Important dosing consideration: Higher doses (250 mg every 2 weeks) produce faster onset of masculinization but are not necessary—lower doses achieve equivalent effects within 6 months with potentially fewer side effects 5. Body mass index may influence dosing requirements, with BMI ≥30 kg/m² potentially requiring more frequent dosing (every 14 days vs every 18 days) 7.

Titration Schedule and Monitoring

Initial Phase (First 3-6 Months)

• Evaluate patient every 2-3 months to assess virilization and adverse effects 1
• Monitor testosterone levels:
  • For gels: anytime after 1 week of treatment 3, 1
  • For injectables: midway between injections 3, 1
• Target testosterone range: 400-700 ng/dL (mid-normal male range) 3, 1
• Adjust dose if testosterone >700 ng/dL or <400 ng/dL 3

Dose Adjustment Algorithm

1. If testosterone <400 ng/dL:
   • Gel: increase from 5 g → 7.5 g → 10 g daily
   • Injectable: increase dose by 25-50 mg or shorten interval
2. If testosterone >700 ng/dL:
   • Reduce dose or extend dosing interval
   • If consistently elevated on lowest dose, consider alternative formulation

Long-Term Monitoring (After 6 Months)

• Clinical evaluation: 1-2 times yearly 1
• Laboratory monitoring:
  • Testosterone levels: every 3-6 months initially, then annually once stable
  • Complete blood count at baseline, 3 months, then every 3-6 months (monitor for polycythemia) 1
  • Hematocrit: baseline, 3-6 months, then annually 3, 1
  • Liver function tests: baseline, every 3 months first year, then 1-2 times yearly 1
  • Lipid profile, fasting glucose: at regular intervals 1
  • Estradiol levels during first 6 months until menses cease (should be <50 pg/mL) 1

Critical Safety Parameters

Hematocrit Monitoring

• If hematocrit >54%: STOP therapy until it decreases to safe level 3, 1
• Evaluate for hypoxia and sleep apnea
• Reinitiate with reduced dose
• Polycythemia occurs in approximately 7% of patients 4

Expected Timeline for Masculinization

• Menstrual cessation: average 2.9 months (85% by 6 months) 6
• Voice deepening: begins within 1 month, dose-dependent early on 5
• Facial hair growth: begins within 1 month, dose-dependent early on 5
• All three doses (125 mg q2wks, 250 mg q2-3wks) achieve similar effects by 6 months 5

Formulation-Specific Considerations

Gel advantages: Easy application, stable levels, good tolerability, ability to start at lower doses for gradual masculinization 4, 8

Gel disadvantages: Risk of transfer to others (cover application site, wash before skin contact), daily application required 3, 9

Injectable advantages: Less frequent dosing, no transfer risk, lower cost, proven efficacy across all formulations (enanthate, cypionate, undecanoate) 8, 5

Injectable disadvantages: Requires injections, potential for level fluctuations (less with weekly vs biweekly dosing), rare injection-related reactions 3

Common Pitfalls to Avoid

1. Starting with excessive doses: The guideline ranges for cisgender hypogonadal men (up to 10 g gel or 200 mg injectable) are often unnecessarily high for FtM patients—start lower and titrate 4, 5

2. Inadequate hematocrit monitoring: Polycythemia is a real risk requiring dose reduction or therapy interruption 1, 4

3. Measuring testosterone at wrong time: For injectables, must measure midway between doses, not at peak or trough 3, 1

4. Ignoring patient goals: Non-binary individuals or those seeking slower masculinization may benefit from lower starting doses (2.5-5 g gel or 25-50 mg weekly injectable) 4

5. Overlooking cardiovascular risk factors: Monitor blood pressure, lipids, and weight regularly as testosterone affects these parameters 1, 8

The evidence base for FtM testosterone therapy comes primarily from guidelines adapted from cisgender male hypogonadism treatment 3, 1 with emerging transgender-specific data supporting lower starting doses and flexible titration based on individual goals 4, 5, 6. All three major formulations (gel, enanthate, cypionate) demonstrate equivalent safety and efficacy at 12 months 8.